Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | TYR | P14679 | 2/20 | 0.61 |
| ▸ | ACHE | P22303 | 1/20 | 0.60 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | MMP9 | P14780 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2853919 | 1.00 | MAPT (0.65) | MAPTTYRACHETRPV1HDAC3 | |
| SCHEMBL802713 | 0.92 | ABCB1 (0.65) | TYRACHETRPV1HDAC3HDAC1 | |
| SCHEMBL1916293 | 0.91 | TYR (0.73) | MAPTTYRACHETRPV1HDAC3 | |
| SCHEMBL12299018 | 0.91 | TYR (0.73) | MAPTTYRACHETRPV1HDAC3 | |
| SCHEMBL2847215 | 0.91 | TYR (0.61) | TYRACHETRPV1HDAC3HDAC1 | |
| SCHEMBL2847211 | 0.91 | TYR (0.61) | TYRACHETRPV1HDAC3HDAC1 | |
| SCHEMBL12246735 | 0.89 | TYR (0.63) | MAPTTYRACHETRPV1HDAC3 | |
| SCHEMBL7523933 | 0.89 | TYR (0.71) | MAPTTYRACHETRPV1HDAC3 | |
| SCHEMBL2875338 | 0.89 | MAPT (0.64) | MAPTTYRACHEMMP9 | |
| SCHEMBL2875339 | 0.89 | MAPT (0.64) | MAPTTYRACHEMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778622-B1 | PARA-ALKYL-SUBSTITUTED N-(4-HYDROXY-3-METHOXY-BENZYL) CINNAMAMIDES AND THE USE THEREOF FOR PRODUCING DRUGS | GRUENENTHAL GMBH (DE) | 2010-01-13 | — | — | EP | claimed |
| US-7541495-B2 | para-alkyl-substituted N-(4-hydroxy-3-methoxy-benzyl)-cinnamamides, pharmaceutical compositions and uses thereof | GRUENENTHAL GMBH (DE) | 2009-06-02 | — | — | US | claimed |
| US-20070208083-A1 | Alkyl-substituted N-(4-hydroxy-3-methoxy-benzyl)-cinnamamides, pharmaceutical compositions and uses thereof | GRUENENTHAL GMBH (DE) | 2007-09-06 | — | — | US | claimed |
| US-7541495-B2 | para-alkyl-substituted N-(4-hydroxy-3-methoxy-benzyl)-cinnamamides, pharmaceutical compositions and uses thereof | GRUENENTHAL GMBH (DE) | 2009-06-02 | — | — | US | disclosed |
| US-20070208083-A1 | Alkyl-substituted N-(4-hydroxy-3-methoxy-benzyl)-cinnamamides, pharmaceutical compositions and uses thereof | GRUENENTHAL GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208083-A1 | Alkyl-substituted N-(4-hydroxy-3-methoxy-benzyl)-cinnamamides, pharmaceutical compositions and uses thereof | CES2, GAA, EGLN3 | MAPT 2566/4885TYR 227/4885ACHE 2638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.